autologous natural killer cell-like cytotoxic T-lymphocytes (Roswell Park Cancer Institute/NCI)

N/A

Report date: 2025/01/26 18:02:15

Base Information

Drug Nameautologous natural killer cell-like cytotoxic T-lymphocytes (Roswell Park Cancer Institute/NCI)
Drug Alias Nameautologous NK cell-like cytotoxic T-lymphocytes (Roswell Park/NCI)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRoswell Park Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A